RD
Ray Dalio (Bridgewater Associates) disclosed increased in ALNYLAM PHARMACEUTICALS INC
Ray Dalio (Bridgewater Associates) filed a 13F change in ALNYLAM PHARMACEUTICALS INC (02043Q107) on 2026-05-15, covering period end 2026-03-31.
Action
Increased
Capital
$1,222,495 reported value
Institutional 13F Signals1 evidence source
Why it matters
This signal is anchored to the SEC filing date while retaining the underlying 13F period end.